IONQ SHAREHOLDER ALERT: Jakubowitz Law Reminds IonQ Shareholders of a Lead Plaintiff Deadline of August 1, 2022 June 3, 2022 5:45 am|NEW YORK, June 3, 2022 /PRNewswire/ — Jakubowitz Law announces that a securities fraud class action lawsuit has commenced…
AMZN SHAREHOLDER ALERT: Jakubowitz Law Reminds Amazon Shareholders of a Lead Plaintiff Deadline of July 5, 2022 June 3, 2022 5:45 am|NEW YORK, June 3, 2022 /PRNewswire/ — Jakubowitz Law announces that a securities fraud class action lawsuit has…
FHS SHAREHOLDER ALERT: Jakubowitz Law Reminds FHS Shareholders of a Lead Plaintiff Deadline of July 11, 2022 June 3, 2022 5:45 am|NEW YORK, June 3, 2022 /PRNewswire/ — Jakubowitz Law announces that a securities fraud class action lawsuit has…
NFLX SHAREHOLDER ALERT: Jakubowitz Law Reminds Netflix, Inc. Shareholders of a Lead Plaintiff Deadline of July 5, 2022 June 3, 2022 5:45 am|NEW YORK, June 3, 2022 /PRNewswire/ — Jakubowitz Law announces that a securities fraud class action lawsuit has…
IIPR SHAREHOLDER ALERT: Jakubowitz Law Reminds Innovative Industrial Properties Shareholders of a Lead Plaintiff Deadline of June 24, 2022 June 3, 2022 5:45 am|NEW YORK, June 3, 2022 /PRNewswire/ — Jakubowitz Law announces that a securities fraud class action lawsuit has commenced…
AXSM SHAREHOLDER ALERT: Jakubowitz Law Reminds Axsome Shareholders of a Lead Plaintiff Deadline of July 12, 2022 June 3, 2022 5:45 am|NEW YORK, June 3, 2022 /PRNewswire/ — Jakubowitz Law announces that a securities fraud class action lawsuit has…
SPRO SHAREHOLDER ALERT: Jakubowitz Law Reminds Spero Shareholders of a Lead Plaintiff Deadline of July 25, 2022 June 3, 2022 5:45 am|NEW YORK, June 3, 2022 /PRNewswire/ — Jakubowitz Law announces that a securities fraud class action lawsuit has…
MARKETO Brings New Values To Modern Digital Marketing in 2022 June 3, 2022 5:32 am|Marketo has been aiming for the greatest values over the past 5 years to strengthen its position and…
Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients June 3, 2022 5:20 am|
ACELYRIN, INC., Affibody AB and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Presented During 2022 European Alliance of Associations for Rheumatology Congress June 3, 2022 5:15 am|